CGM as Diagnostic Tool in Observing Steroid-Induced Hyperglycemia

CompletedOBSERVATIONAL
Enrollment

71

Participants

Timeline

Start Date

April 17, 2024

Primary Completion Date

March 21, 2025

Study Completion Date

March 21, 2025

Conditions
DiabetesPain Management
Interventions
DEVICE

Dexcom G7

The study will be conducted as a single-arm trial consisting of participants enrolled in the test group. Each participant will receive a G7 CGM and their blood glucose levels will be continuously transmitted to the Dexcom Clarity system for monitoring and data collection. As a observational study, the test group glucose levels will be monitored after receiving a steroid for pain management. The CGM profile of steroid-induced hyperglycemia in patients will be studied for the following corticosteroids: dexamethasone (10 mg), methylprednisolone (40 mg or 80 mg), triamcinolone (40 mg or 80 mg).

Trial Locations (2)

68803

Grand Island Pain Relief Center, Grand Island

68901

Hastings Pain Relief Center, Hastings

All Listed Sponsors
lead

Mahesh Pattabiraman

INDUSTRY

NCT06628284 - CGM as Diagnostic Tool in Observing Steroid-Induced Hyperglycemia | Biotech Hunter | Biotech Hunter